Grifols stock: US biopharma IPO focus frames latest quote
Published on 11/19/2026 at 17:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSIPO review and latest trading
- Grifols is weighing a minority listing of its US Biopharma business while retaining majority ownership.
- The Lang & Schwarz quote was 4.48 percent below the level reported on November 14.
Grifols stock remains in focus as the company weighs a minority IPO for its US Biopharma business. The Lang & Schwarz quote stood at 11.10 euros at 17:06 CET on Thursday, November 19. That was 4.48 percent below the 11.62-euro quote in the company's November 14 market report.
IPO review remains central
The proposed transaction would allow Grifols to raise equity capital while retaining majority ownership of the US operation. Proceeds are intended to support debt reduction, with the eventual financial effect depending on the stake sold, valuation, timing and investor demand.
The IPO review follows third-quarter growth led by Biopharma. The division's revenue rose 10.3 percent at constant currency, while group revenue increased 8.4 percent to 2.04 billion euros and adjusted EBITDA rose 9.8 percent to 538 million euros.
Deleveraging shapes investor view
Net leverage under the credit-agreement definition stood at 3.98 times at the end of September. The potential listing therefore adds a possible funding route to the group's deleveraging effort, but it is not completed debt reduction.
For investors, the key variables remain the transaction structure, market conditions and any timetable for execution. The latest quote puts the stock below its November 14 level as the IPO discussion continues to frame the capital-allocation debate.
Grifols stock at a glance
- Company: Grifols, S.A.
- ISIN: ES0171996087
- Trading venue: Lang & Schwarz
- Quote: 11.10 euros, Thursday, November 19, 2026, 17:06 CET
- Change since November 14: -4.48 percent from 11.62 euros
Spanish equities remain the broader market context; see Current market reports.
